Colorectal cancer/adenomas Cancer
Conditions
Interventions
All individuals fulfilling the inclusion criteria will be enrolled. After the refinement of participants by the exclusion criteria, blood samples will be drawn for neurotensin and IL-8 testing by ELIS
Sponsors
University Hospitals of Morecambe Bay
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged over 50 years 2. Referred for colonoscopy for any suspected indication
Exclusion criteria
Exclusion criteria: 1. Need for emergency surgery 2. Presence of inflammatory bowel disease 3. Known history of inherited colorectal cancer 4. History of cancer in another primary site 5. Presence of liver metastases (since neurotensin is metabolized in the liver) 6. Negative previous colonoscopy for cancer 7. Haemolysis in serum samples 8. Informed consent not signed or patient withdrew consent 9. Persons who will not have the capacity to decide for themselves, who are unable to represent their own interests or are particularly susceptible to coercion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Serum neurotensin measured by Human Neurotensin (NT) ELISA Kit (Cusabio) 2. Serum IL-8 values measured by ELISA (test brand tbc) 3. Diagnosis of colorectal cancer or adenoma using colonoscopy and histology reports | — |
Secondary
| Measure | Time frame |
|---|---|
| Diagnostic performance compared to the current screening system | — |
Countries
England, United Kingdom
Contacts
Public ContactGeorgios Sgourakis
Outcome results
None listed